Contrasting Zenas BioPharma (ZBIO) & Its Competitors

Zenas BioPharma (NASDAQ:ZBIO) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its rivals? We will compare Zenas BioPharma to related businesses based on the strength of its earnings, analyst recommendations, dividends, valuation, risk, profitability and institutional ownership.

Analyst Recommendations

This is a summary of current ratings and target prices for Zenas BioPharma and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zenas BioPharma	1	2	6	0	2.56
Zenas BioPharma Competitors	9861	15274	45589	1597	2.54

Zenas BioPharma presently has a consensus price target of $46.71, suggesting a potential upside of 62.77%. As a group, “Biotechnology” companies have a potential upside of 120.58%. Given Zenas BioPharma’s rivals higher probable upside, analysts plainly believe Zenas BioPharma has less favorable growth aspects than its rivals.

Profitability

This table compares Zenas BioPharma and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zenas BioPharma	N/A	-144.65%	-59.83%
Zenas BioPharma Competitors	-12,323.33%	-195.38%	-30.39%

Earnings & Valuation

This table compares Zenas BioPharma and its rivals revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Zenas BioPharma	$10.00 million	-$377.74 million	-3.05
Zenas BioPharma Competitors	$727.58 million	$11.89 million	-18.07

Zenas BioPharma’s rivals have higher revenue and earnings than Zenas BioPharma. Zenas BioPharma is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Institutional & Insider Ownership

47.8% of shares of all “Biotechnology” companies are held by institutional investors. 22.0% of Zenas BioPharma shares are held by insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Risk & Volatility

Zenas BioPharma has a beta of -0.88, meaning that its share price is 188% less volatile than the S&P 500. Comparatively, Zenas BioPharma’s rivals have a beta of -1.84, meaning that their average share price is 284% less volatile than the S&P 500.

Zenas BioPharma Company Profile

Zenas BioPharma is a clinical-stage biopharmaceutical company focused on developing treatments for autoimmune diseases. Founded in 2019 and based in Waltham, Massachusetts, the company describes itself as a global biopharmaceutical business. Its lead investigational medicine, obexelimab, is a bifunctional antibody designed to bind CD19 and FcγRIIb and inhibit B-cell activity. Zenas is developing the drug for autoimmune conditions, including IgG4-related disease; it has not been approved for commercial use.